.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Dow
Fish and Richardson
Chinese Patent Office
Baxter
Medtronic
Express Scripts
Federal Trade Commission
Harvard Business School
Daiichi Sankyo

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Novel 17.beta.-hydroxy-19-nor-steroids
Abstract:Novel 19-nor steroids of the formula ##STR1## wherein R' is selected from the group consisting of propyl, propenyl, iodoethenyl, iodoethynyl or --C.tbd.C--CH.sub.2 --Hal.sub.1, Hal.sub.1 is selected from the group consisting of fluorine, chlorine and bromine and their non-toxic, pharmaceutically acceptable acid addition salts having a remarkable antiglucocorticoid and antiprogestomimetic activity.
Inventor(s): Moguilewsky; Martine (Paris, FR), Nedelec; Lucien (Le Raincy, FR), Nique; Francois (Pavillons-Sous-Bois, FR), Philibert; Daniel (La Varenne Saint-Hilaire, FR)
Assignee: Roussel Uclaf (Paris, FR)
Filing Date:Dec 30, 1988
Application Number:07/292,475
Claims:1. A compound selected from the group consisting of 19-nor steroids of the formula ##STR12## wherein R' is selected from the group consisting of propyl, prop-1-enyl, iodoethenyl, iodoethynyl or --C.tbd.C--CH.sub.2 --Hal.sub.1, Hal.sub.1 is selected from the group consisting of fluorine, chlorine and bromine and their non-toxic, pharmaceutically acceptable acid addition salts.

2. A compound of claim 1 selected from the group consisting of 17.alpha.-(3-chloro-1-propynyl)-11.beta.-[4-(dimethylamino)-phenyl]-.DELTA ..sup.4,9 -estradien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

3. A compound of claim 1 selected from the group consisting of 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-(3-fluoro-1-propynyl)-.DELTA ..sup.4,9 -estradien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

4. A compound of claim 1 selected from the group consisting of 11.beta.-[4-(dimethylamino)-phenyl]-21-iodo-19-nor-17.alpha.-.DELTA..sup.4 ,9 -pregnadien-20-yn-17.beta.-ol-3-one and its non-toxic, pharmaceuticaly acceptable acid addition salts.

5. A compound of claim 1 selected from the group consisting of (E) 11.beta.-[4-(dimethylamino)-phenyl]21-iodo-19-nor-17.alpha.-.DELTA..sup.4, 9,20 -pregnatrien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

6. A compound of claim 1 selected from the group consisting of (Z) 11.beta.-[4-(dimethylamino)-phenyl]21-iodo-19-nor-17.alpha.-.DELTA..sup.4, 9,20 -pregnatrien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

7. A compound of claim 1 selected from the group consisting of 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-[(Z)-1-propenyl]-.DELTA..sup .4,9 -estradien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

8. A compound of claim 1 selected from the group consisting of 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-propyl-.DELTA..sup.4,9 -estradien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

9. A compound of claim 1 selected from the group consisiting of 17.alpha.-(3-bromo-1-propynyl)-11-.beta.[4-(dimethylamino)-phenyl]-.DELTA. .sup.4,9 -estradien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

10. An antiglucocorticoid composition comprising an antiglucocorticoidally effective amount of at least one compound of claim 1 and an inert pharmaceutical carrier.

11. A composition of claim 10 wherein the active compound is selected from the group consisting of 17.alpha.-(3-chloro-1-propynyl)-11.beta.-[4-(dimethylamino)-phenyl]-.DELTA ..sup.4,9 -estradien-17.beta.-ol-3-one, 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-(3-fluoro-1-propynyl)-.DELTA ..sup.4,9 -estradien-17.beta.-ol-3-one, 11.beta.-[4-(dimethylamino)-phenyl]-21-iodo-19-nor-17.alpha.-.DELTA..sup.4 ,9 -pregnadien-20-yn-17.beta.-ol-3-one, (E) 11.beta.-[4-(dimethylamino)-phenyl]-21-iodo-19-nor-17.alpha.-.DELTA..sup.4 ,9,20 -pregnatrien-17.beta.-ol-3-one, (Z) 11.beta.-[4-(dimethylamino)-phenyl]-21-iodo-19-nor-17.alpha.-.DELTA..sup.4 ,9,20 -pregnatrien-17.beta.-ol-3-one, 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-[(Z)-1-propenyl)-.DELTA..sup .4,9 -estradien-17.beta.-ol-3-one, 11.beta.-[4-(dimethylamino)-phenyl)]-17.alpha.-propyl-.DELTA..sup.4,9 -estradien-17.beta.-ol-3-one and 17.alpha.-(3-bromo-1-propynyl)-11.beta.-[4-(dimethylamino)-phenyl]-.DELTA. .sup.4,9 -estradien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

12. A composition of claim 10 wherein the active compound is selected from the group consisting of 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-(3-fluoro-1-propynyl)-.DELTA ..sup.4,9 -estradien-17.beta.-ol-3-one, (Z) 11.beta.-[4-(dimethylamino)-phenyl]-21-iodo-19-nor-17.alpha.-.DELTA..sup.4 ,9,20 -pregnatrien-17.beta.-ol-3-one and 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-[(Z)-1-propenyl]-.DELTA..sup .4,9 -estradien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

13. An abortifacient composition for animals comprising an abortifaciently effective amount of the compound of claim 1 and pharmaceutical carrier.

14. A composition of claim 13 comprising an effective amount of the compounds of claim 3 and 11.

15. A composition of claim 13 for animals comprising an effective amount of the compound of claim 12.

16. A method of inducing antiglucocorticoid activity in warm-blooded animals comprising administering to warm-blooded animals an antiglucocorticoidally effective amount of at least one compound of claim 1.

17. A method of claim 16 wherein the active compound is selected from the group consisting of 17.alpha.-(3-chloro-1-propynyl)-11.beta.-[4-(dimethylamino)-phenyl]-.DELTA ..sup.4,9 -estradien-17.beta.-ol-3one, 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-(3-fluoro-1-propynyl)-.DELTA ..sup.4,9 -estradien-17.beta.-ol-3-one, 11.beta.-[4-(dimethylamino)-phenyl]-21-iodo-19-nor-17.alpha.-.DELTA..sup.4 ,9 -pregnadien-20-yn-17.beta.-ol-3-one, (E) 11.beta.-[4-(dimethylamino)-phenyl]-21-iodo-19-nor-17.alpha.-.DELTA..sup.4 ,9,20 -pregnatrien-17.beta.-ol-3-one, (Z) 11.beta.-[4-(dimethylamino)-phenyl]-21-iodo-19-nor-17.alpha.-.DELTA..sup.4 ,9,20 -pregnatrien-17.beta.-ol-3-one, 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-[(Z)-1-propenyl)-.DELTA..sup .4,9 -estradien-17.beta.-ol-3-one, 11.beta.-[4-(dimethylamino)-phenyl)]-17.alpha.-propyl-.DELTA..sup.4,9 -estradien-17.beta.-ol-3-one and 17.alpha.-(3-bromo-1-propynyl)-11.beta.-[4-(dimethylamino)-phenyl]-.DELTA. .sup.4,9 -estradien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

18. A method of claim 16 wherein the active compound is selected from the group consisting of 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-(3-fluoro-1-propynyl)-.DELTA ..sup.4,9 -estradien-17.beta.-ol-3-one, (Z) 11.beta.-[4-(dimethylamino)-phenyl]-21-iodo-19-nor-17.alpha.-.DELTA..sup.4 ,9,20 -pregnatrien-17.beta.-ol-3-one and 11.beta.-[4-(dimethylamino)-phenyl]-17.alpha.-[(Z)-1-propenyl]-.DELTA..sup .4,9 -estradien-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.

19. A method of inducing abortion in pregnant female warm-blooded animals comprising administering to pregnant fermale warm-blooded animals an abortion effective amount of the compound of claim 1.

20. A method of claim 19 comprising administering to pregnant female warm-blooded animals an abortion effective amount of the compound of claim 3 and 11.

21. A method of claim 19 comprising administering to pregnant female warm-blooded animals an abortion effective amount of the compound of claim 7.

22. An anti-progestomimetic composition comprising an anti-progestomimetically effective amount of at least one compound of claim 1 and an inert pharmaceutical carrier.

23. A method of inducing anti-progestomimetic activity in warm-blooded animals comprising administering to warm blooded animals an anti-progestomimetically effective amount of at least one compound of claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Julphar
Argus Health
Queensland Health
US Department of Justice
Chubb
Cipla
Chinese Patent Office
Mallinckrodt
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot